Simulated Comparison of the Pharmacodynamics of Ciprofloxacin and Levofloxacin Against Pseudomonas aeruginosa Using Pharmacokinetic Data from Healthy Volunteers and 2002 Minimum Inhibitory Concentration Data

Clinical Therapeutics

Volumn 29, Issue 7, 2007, Pages 1421-1427

  Burgess, David S ^a,b   Hall II, Ronald G ^c,d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

ciprofloxacin; levofloxacin; pharmacodynamics; Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; LEVOFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; MEDLINE; MESH HEADING; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PSEUDOMONAS AERUGINOSA; SIMULATION;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; OFLOXACIN; PSEUDOMONAS AERUGINOSA;

EID: 34548355192     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.024     Document Type: Article

References (32)

1. Gemifloxacin Surveillance Study Research Group, Hoban D., Bouchillon S., Johnson J., et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microbiol Infect Dis. 40 (2001) 51-57
2. Zhanel G., Ennis K., Vercaigne L., et al. A critical review of the fluoroquinolones: Focus on respiratory infections. [published correction appears in Drugs. 2002;62:944]. Drugs 62 (2002) 13-59
3. Rubio T., and Shapiro C. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother. 18 Suppl D (1986) 147-152
4. Gales A., Jones R., Turnidge J., et al. Characterization of Pseudomonas aerugmosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 32 Suppl 2 (2001) S146-S155
5. West M., Boulanger B., Fogarty C., et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study. Clin Ther. 25 (2003) 485-506
6. Ambrose P., Bhavnani S., Rubino C., et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. [published correction appears in Clin Infect Dis. 2007;44:624]. Clin Infect Dis. 44 (2007) 79-86
7. Ambrose P. Monte Carlo simulation in the evaluation of susceptibility breakpoints: Predicting the future: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 26 (2006) 129-134
8. Chow A., Fowler C., Williams R., et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 45 (2001) 2122-2125
9. Shah A., Lettieri J., Kaiser L., et al. Comparative pharmacokinetics and safety of ciprofloxacin 400 mg IV thrice daily versus 750 mg PO twice daily. J Antimicrob Chemother. 33 (1994) 795-801
10. Lettieri J., Rogge M., Kaiser L., et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 36 (1992) 993-996
11. Forrest A., Nix D., Ballow C., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 37 (1993) 1073-1081
12. Jones R., Rubino C., Bhavnani S., Ambrose P., and Anti-microbial Resistance Rate Epidemiology Study Team Program. World-wide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Anti-microbial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 47 (2003) 292-296
13. Ambrose P., Owens Jr. R., Garvey M., and Jones R. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother. 49 (2002) 445-453
14. Ambrose P., Bhavnani S., and Jones R. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: Report from the ARREST program. Antimicrob Agents Chemother. 47 (2003) 1643-1646
15. Frei C., and Burgess D. Pharmaco-dynamic analysis of ceffriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy. 25 (2005) 1161-1167
16. Moczygemba L., Frei C., and Burgess D. Pharmacodynamic modeling of carbapenems and fluoroquino-Iones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther. 26 (2004) 1800-1807
17. Montgomery M., Beringer P., Aminimanizani A., et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 45 (2001) 3468-3473
18. Craig W., and Ebert S. Protein binding and its significance in antibacterial therapy. Infect Dis Clin North Am. 3 (1989) 407-414
19. Andes D., and Craig W. Animal model pharmacokinetics and pharmaco-dynamics: A critical review. Int J Antimicrob Agents. 19 (2002) 261-268
20. Mouton J., Dudley M., Cars O., et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 19 (2002) 355-358
21. Preston S., Redell M., Chein S., et al. Evaluation of the target attainment rate of levofloxacin and ciprofloxacin for intensive care unit patients. Paper presented at: 10th International Congress on Infectious Diseases (March 11-14, 2002) Singapore
22. Fluit A., Verhoef J., Schmitz F., and European SENTRY Participants. Antimicrobial resistance in European isolates of Pseudornonas aerugnosa. Eur J Clin Microbiol Infect Dis. 19 (2000) 370-374
23. Goossens H. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: Comparison of antibiotic susceptibilities between countries and centre types. J Antimicrob Chernother. 46 Suppl B (2000) 39-52
24. Gordon K., Pfaller M., Jones R., and SENTRY Participants Group. BMS284756 (formerly T-3811, a desfluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). J Antimicrob Chemother. 49 (2002) 851-855
25. Turner P. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview. J Antimicrob Chemother. 46 Suppl B (2000) 9-23
26. Van Eldere J. Multicentre surveillance of Pseudomonas aerugmosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother. 51 (2003) 347-352
27. Fekete T., Tumah H., Woodwell J., et al. Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 anti- microbial agents in a tertiary-care university hospital. Am J Med. 100 (1996) 20S-25S
28. Dudley M. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med. 91 (1991) 45S-50S
29. Karlowsky J., Kelly L., Thornsberry C., et al. Susceptibility to fluoroquinolones among commonly isolated gram-negative bacilli in 2000: TRUST and TSN data For the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents 19 (2002) 21-31
30. Chen H., Yuan M., Ibrahim-Elmagboul I., and Livermore D. National survey of susceptibility to antimicrobials amongst clinical isolates oF Pseudomonas aerugmosa. J Antimicrob Chemother. 35 (1995) 521-534
31. Neuhauser M., Weinstein R., Rydman R., et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications For fluoroquinolone use. JAMA. 289 (2003) 885-888
32. Masterton R. Ciprofloxacin resistance-'searly-warning' signs From the MYSTIC surveillance programme?. J Antimicrob Chemotker. 49 (2002) 218-220